Dupilumab (Dupixent®) is accepted for restricted use within NHS Scotland

Source:
Scottish Medicines Consortium - SMC
Publisher:
Scottish Medicines Consortium
Publication date:
13 January 2020

Abstract

Dupilumab is accepted for use in NHS Scotland for moderate-to-severe atopic dermatitis in adolescents (=12 to <18 years) who are candidates for systemic therapy, restricted to use in those with inadequate response to systemic immunosuppressants such as ciclosporin.